Apply for Tasigna (Nilotinib) Copay Assistance & Copay Card | Nilotinib Patient Assistance | QuickRx

Tasigna copay assistance and nilotinib copay assistance programs help reduce or eliminate the out-of-pocket costs that patients pay for their medication. These programs are available through manufacturer-sponsored Tasigna copay cards, generic nilotinib copay cards, and independent patient assistance programs.

What QuickRx provides at no cost:

• Complete application assistance for copay cards and financial aid programs
• Insurance benefit verification and coverage analysis
• Continuous benefit monitoring to maintain your savings
• Home delivery coordination and prescription management
• Automatic refill reminders

Tasigna savings programs available:

For commercially insured patients: Manufacturer copay cards can reduce your prescription costs, with many eligible patients paying significantly less out-of-pocket. Both brand Tasigna and generic nilotinib copay cards are available.

For Medicare patients: Independent foundation grant programs offer financial assistance to help cover medication expenses. These nonprofit programs are free to apply for, and QuickRx guides you through the entire process.

For uninsured or underinsured patients: Patient assistance programs may provide Tasigna at no cost or significantly reduced prices based on household income and medical necessity.

Eligibility depends on your insurance type, medical diagnosis, and financial circumstances. Here’s how QuickRx makes enrollment simple:

Step 1: Reach out to QuickRx
Call (917) 830-2525 or toll-free (800) 496-6111, or complete our confidential online enrollment form.

Step 2: Insurance Review
Our team verifies your coverage and identifies which copay assistance programs match your insurance type.

Step 3: Qualification Assessment
We review eligibility requirements for each program—insurance type and diagnosis confirmation.

Step 4: Application Support
We handle all paperwork and follow up with each program to ensure timely approval.

General eligibility by insurance type:

Commercial Insurance: Most patients with employer-sponsored or marketplace insurance qualify for manufacturer copay cards. Both brand Tasigna and generic nilotinib copay cards are available.

Medicare Part D: Foundation grants available for eligible patients. As of 2025, Medicare Part D includes a $2,000 annual out-of-pocket cap. QuickRx helps identify programs you may qualify for.

No Insurance: Patient assistance programs may provide medication to eligible patients. QuickRx helps you apply and navigate these programs.

Yes! While federal law prohibits manufacturer copay cards for Medicare Part D beneficiaries, QuickRx connects Medicare patients to independent charitable foundations that provide grants to cover Tasigna costs.

How foundation grants work for Medicare patients:

Foundation Grant Programs:

• Independent nonprofit organizations offer financial assistance for Medicare patients
• Grants cover Part D deductibles, coinsurance, and copays
• Eligibility requirements vary by foundation
• Renewable grants every 3-12 months

Key foundations for CML patients include:

• Leukemia & Lymphoma Society (LLS)
• CancerCare
• Patient Advocate Foundation Co-Pay Relief Program

Medicare Extra Help/Low-Income Subsidy:

• Federal program that reduces or eliminates Part D premiums, deductibles, and copays
• For beneficiaries who meet eligibility requirements
• QuickRx helps you understand eligibility and apply

2025 Medicare Part D Out-of-Pocket Cap:

• Medicare Part D now includes a $2,000 annual out-of-pocket maximum
• Once you reach this cap, you pay $0 for covered medications the rest of the year

QuickRx handles everything:

• Foundation grant applications and renewals
• Grant eligibility screening
• Documentation gathering
• Follow-up with foundations to ensure timely approval

Most Medicare patients we serve access foundation grants that cover their Tasigna costs, making treatment affordable. Contact us at (917) 830-2525 to discuss your options.

Applying is simple. Complete the secure form on this page, and one of our patient navigators will contact you to guide you through the enrollment process. We handle the paperwork and coordinate with your healthcare provider to make the process as smooth as possible.

Here’s what to expect:

Step 1: Submit your information through our online form or call us directly.

Step 2: A dedicated patient navigator reviews your insurance and identifies all programs you may qualify for—including brand Tasigna and generic nilotinib options.

Step 3: We complete applications on your behalf and submit all required documentation.

Step 4: Once approved, we coordinate your prescription and arrange delivery.

The entire process typically takes just a few days, and you’ll know your exact out-of-pocket cost before your first order ships.

No. QuickRx Specialty Pharmacy offers completely free enrollment support for Tasigna (nilotinib) copay assistance programs. We don’t charge application fees or service charges—our mission is to help CML patients access affordable treatment.

What’s included at no cost:

• Complete application assistance for copay cards and financial aid programs
• Insurance benefit verification and coverage analysis
• Prior authorization support
• Continuous benefit monitoring to maintain your savings
• Home delivery coordination and prescription management
• Automatic refill reminders

QuickRx’s specialty pharmacy team works to eliminate financial barriers to your CML treatment, allowing you to focus on your health.

Tasigna (nilotinib) is an FDA-approved prescription medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in adults and children 1 year of age and older.

What is Chronic Myeloid Leukemia?

CML is a type of cancer that starts in the blood-forming cells of the bone marrow. In CML, a genetic change creates an abnormal chromosome called the Philadelphia chromosome, which produces an abnormal protein (BCR-ABL) that causes leukemia cells to grow and multiply uncontrollably.

How Tasigna (nilotinib) helps CML patients:

Blocks Cancer Cell Growth: Tasigna is a BCR-ABL tyrosine kinase inhibitor (TKI) that blocks the abnormal protein driving CML cell growth.

Achieves Deep Responses: Clinical trials showed many patients achieve major molecular response (MMR) or deeper, meaning very low levels of leukemia cells.

Enables Treatment-Free Remission: Some patients who achieve sustained deep molecular responses may become eligible to stop treatment while remaining in remission.

FDA-Approved Indications:

• Newly diagnosed Ph+ CML in chronic phase (adults and pediatric patients ≥1 year)
• Previously treated Ph+ CML in chronic or accelerated phase in patients resistant or intolerant to prior therapy including imatinib (adults and pediatric patients ≥1 year)

FDA Approval: Tasigna was first approved by the FDA on October 29, 2007.

Yes! Generic nilotinib became available in the United States in May 2025 when Apotex launched the first FDA-approved generic version. Additional manufacturers including Cipla have also received FDA approval.

Generic nilotinib details:

• Available in the same strengths as brand Tasigna: 50 mg, 150 mg, and 200 mg capsules
• FDA-approved as therapeutically equivalent to brand Tasigna
• Contains the same active ingredient and works the same way in your body
• Typically costs 30-80% less than brand-name Tasigna

Generic nilotinib copay cards available:

Apotex Nilotinib Instant Savings Card:

• Commercially insured patients may pay significantly less out-of-pocket
• Covers costs up to program limits per 30-day supply

Cipla Nilotinib Savings Card:

• Eligible commercially insured patients may reduce their out-of-pocket costs significantly

Should you switch to generic nilotinib?
Generic nilotinib is therapeutically equivalent to brand Tasigna, meaning it works the same way. Switching may significantly reduce your out-of-pocket costs. However, discuss any medication changes with your oncologist. QuickRx can help you compare costs between brand and generic options for your specific insurance plan.

The Tasigna copay card is a manufacturer-sponsored savings program that helps commercially insured patients reduce their out-of-pocket costs for brand-name Tasigna.

How the Tasigna copay card works:

Savings Amount:

• Eligible patients may pay significantly less per month
• Manufacturer covers costs up to annual program limits toward copays and coinsurance

How to use it:

• Present the card at your pharmacy when filling your prescription
• Savings are applied automatically at the point of sale
• Can be used for each fill throughout the year until the annual maximum is reached

Eligibility requirements:

• Must have commercial (private) health insurance
• Medicare, Medicaid, and other government-insured patients are NOT eligible
• No income restrictions for commercially insured patients

What happens when you reach the annual limit?
If you reach the annual limit, QuickRx proactively helps you identify backup options such as foundation grants, patient assistance programs, or switching to generic nilotinib copay cards with separate annual limits.

QuickRx handles complete enrollment in the Tasigna copay card program at no cost to you.

Tasigna (nilotinib) capsules are taken orally twice daily, approximately 12 hours apart. There are important food restrictions that must be followed.

Critical Food Restriction:

Tasigna capsules must be taken on an empty stomach:

• Do not eat for at least 2 hours BEFORE taking Tasigna
• Do not eat for at least 1 hour AFTER taking Tasigna

This food restriction is critical because taking nilotinib with food significantly increases drug levels in your blood, which can cause dangerous side effects including heart rhythm abnormalities.

Standard Dosing:

• Newly diagnosed CML (chronic phase): 300 mg twice daily
• Resistant/intolerant CML (chronic or accelerated phase): 400 mg twice daily
• Pediatric patients: 230 mg/m² twice daily, maximum 400 mg per dose

Administration Tips:

• Swallow capsules whole with water
• If you cannot swallow capsules, you may open them and mix the contents with one teaspoon of applesauce—use immediately and do not save for later
• Take doses at the same times each day, approximately 12 hours apart
• Avoid grapefruit and grapefruit juice during treatment
• If you miss a dose, do not double up—take your next dose at the regular time

Important Note: A different formulation called Danziten (nilotinib tartrate tablets) can be taken with or without food, but it has different dosing and is NOT interchangeable with Tasigna capsules on a mg-per-mg basis.

Like all medications, Tasigna (nilotinib) can cause side effects. It’s important to discuss these with your healthcare provider. According to clinical information from MedlinePlus, here are potential side effects:

Boxed Warning – QT Prolongation:
Tasigna can prolong the QT interval on ECG, which may cause dangerous heart rhythm abnormalities. Sudden deaths have been reported. Your doctor will monitor your heart with ECGs and check your potassium and magnesium levels regularly.

Very Common Side Effects (more than 1 in 10 people):

• Skin rash, itching, hair thinning, dry skin, night sweats
• Nausea, vomiting, diarrhea, constipation, abdominal pain
• Headache, fatigue, muscle/joint pain, muscle cramps
• Low blood cell counts (monitored with regular blood tests)

Common Side Effects (up to 1 in 10 people):

• High blood pressure
• Peripheral edema (swelling)
• Upper respiratory infections
• Back pain, bone pain

Serious Side Effects (Seek medical attention immediately):

• Chest pain, irregular or fast heartbeat, shortness of breath
• Signs of serious bleeding (vomiting blood, black stools)
• Signs of liver problems (yellowing skin/eyes, dark urine)
• Signs of pancreatitis (severe stomach pain radiating to back)
• Signs of serious infection (fever, chills, persistent cough)

Required Monitoring:
Your healthcare team will monitor you with regular blood tests, liver function tests, lipase levels, and ECGs during treatment.

Tasigna (nilotinib) may not be appropriate for everyone. Your oncologist will evaluate your medical history to determine if Tasigna is right for you.

Tasigna should NOT be taken if you have:

• Low potassium (hypokalemia)
• Low magnesium (hypomagnesemia)
• Long QT syndrome or other heart rhythm disorders
• Severe liver impairment (use with caution)

Important Considerations:

Pregnancy Prevention:

• Women must not be pregnant when starting Tasigna
• Verify pregnancy status before starting treatment
• Use effective contraception during treatment and for 14 days after the last dose

Breastfeeding:

• Do not breastfeed during treatment or for 14 days after the last dose

Drug Interactions:

• Avoid grapefruit and grapefruit juice
• Avoid St. John’s Wort
• Avoid medications that prolong the QT interval
• Avoid strong CYP3A4 inhibitors or inducers
• Tell your doctor about all medications you take

Food Restrictions:

• Must be taken on an empty stomach (2 hours after and 1 hour before food)

Your healthcare team will review your complete medical history, medications, and perform necessary tests before prescribing Tasigna.

Tasigna is not traditional chemotherapy. While it is used to treat cancer, nilotinib is classified as a targeted therapy—specifically, a tyrosine kinase inhibitor (TKI).

How targeted therapy differs from chemotherapy:

Traditional Chemotherapy:

• Kills rapidly dividing cells throughout the body
• Affects both cancerous AND healthy cells
• Causes widespread side effects (hair loss, severe nausea, immune suppression)
• Given in cycles with recovery periods

Tasigna (Targeted Therapy):

• Specifically targets the BCR-ABL protein that drives CML cell growth
• More precise mechanism of action
• Generally fewer systemic side effects than traditional chemotherapy
• Taken continuously as oral medication

However, important to know:

• Nilotinib is still classified as a hazardous medication
• Requires careful handling and regular monitoring
• Can cause serious side effects including heart rhythm changes
• Regular blood tests and monitoring are required

Tasigna represents a significant advancement in CML treatment, allowing many patients to take an oral medication at home rather than receiving IV chemotherapy infusions.

Tasigna (nilotinib) has demonstrated significant efficacy in clinical trials for Philadelphia chromosome-positive chronic myeloid leukemia.

Key Clinical Trial Results (ENESTnd Study):

Response Rates:

• Higher rates of major molecular response (MMR) compared to imatinib at 12 months
• Faster and deeper responses achieved
• Lower rates of progression to accelerated or blast phase

Treatment-Free Remission:

• Patients who achieve sustained deep molecular response (MR4.5) for at least one year may be eligible to discontinue treatment
• Many patients who stop treatment maintain remission without medication
• Regular monitoring required to detect any loss of response

Long-Term Benefits:

• Many patients remain in remission for years on therapy
• Durable responses with continued treatment
• Quality of life maintained with oral medication

Response Monitoring:
Your oncologist will monitor your response using PCR blood tests that measure BCR-ABL transcript levels. Response milestones include:

• Complete hematologic response
• Complete cytogenetic response
• Major molecular response (MMR)
• Deep molecular response (MR4, MR4.5)

Blood tests and health monitoring are essential before, during, and after Tasigna treatment to ensure safety.

Before Starting Treatment:

• Complete blood count (CBC)
• Liver function tests
• Electrolytes (potassium, magnesium)
• ECG to check heart rhythm (QTc interval)
• Lipase levels
• Blood glucose and lipid panel

During Treatment:

• ECG at baseline, 7 days after starting, and periodically thereafter
• Blood counts regularly (weekly initially, then monthly)
• Liver function tests periodically
• Lipase levels periodically
• Electrolytes as needed
• PCR testing to monitor molecular response (typically every 3 months)

Why Monitoring Matters:

• Detects QT prolongation early (heart rhythm safety)
• Monitors blood cell counts for myelosuppression
• Checks liver function for hepatotoxicity
• Monitors for pancreatitis (elevated lipase)
• Tracks disease response through molecular testing

Correcting Abnormalities:
If low potassium or magnesium is detected, these must be corrected before continuing treatment. Your healthcare provider may adjust dosing based on lab results.

Yes! QuickRx Specialty Pharmacy offers free nationwide home delivery of Tasigna (nilotinib) and generic nilotinib with appropriate packaging to ensure medication integrity.

What’s included with QuickRx home delivery:

Free Shipping:

• No delivery charges
• Secure packaging
• Signature required for security
• Tracking provided

Coordination with Treatment Schedule:

• Delivery timed to ensure continuous supply
• You receive medication when you need it
• Reminder communications before refills are due

Discreet Packaging:

• Plain packaging with no medication information visible
• Protects your privacy

Flexible Delivery:

• Choose delivery dates that work for your schedule
• Coordination with your healthcare provider’s treatment plan

24/7 Pharmacist Support:

• Questions about your medication answered anytime
• Side effect guidance
• Drug interaction checks

Call (917) 830-2525 or (800) 496-6111 to set up home delivery with copay assistance enrollment.

Getting started with Tasigna through QuickRx Specialty Pharmacy is easy. Our team handles the complex coordination so you can focus on your health.

Here’s how to begin:

Step 1: Contact Us

• Call (917) 830-2525 or toll-free (800) 496-6111
• Or complete the secure online form on this page

Step 2: We Verify Your Benefits

• Our team contacts your insurance to verify coverage
• We identify all copay assistance programs you may qualify for
• We compare brand Tasigna vs. generic nilotinib costs for your plan
• We provide a personalized cost estimate

Step 3: Copay Assistance Enrollment

• We complete applications for manufacturer copay cards, patient assistance programs, or foundation grants
• You provide basic information and documentation
• We handle all follow-up with programs

Step 4: Prescription Coordination

• We work with your oncologist to obtain your prescription
• Prior authorization handled if required
• All paperwork managed by our team

Step 5: Delivery

• Free home delivery to your door
• Ongoing support throughout your treatment
• 24/7 pharmacist access

Don’t let cost concerns delay your CML treatment. Contact QuickRx today and let us help you access the copay assistance you need.

For a more in-depth breakdown of Tasigna patents and their expirations, click here to see the page on Drugs.com 

Medical References

References

1. National Cancer Institute. Chronic Myelogenous Leukemia Treatment (PDQ) – Patient Version. Accessed December 2025.
2. Mayo Clinic. Chronic Myelogenous Leukemia – Symptoms and Causes. Accessed December 2025.
3. Cleveland Clinic. Chronic Myeloid Leukemia (CML). Accessed December 2025.
4. MedlinePlus. Nilotinib Drug Information. Accessed December 2025.
5. American Cancer Society. Chronic Myeloid Leukemia Overview. Accessed December 2025.
6. Leukemia & Lymphoma Society. Chronic Myeloid Leukemia Resources. Accessed December 2025.

Disclaimer: This page provides general information about Tasigna (nilotinib) copay assistance and is not medical advice. Patients should consult their healthcare provider for complete information about Tasigna, including full prescribing information, potential side effects, and whether it’s appropriate for their condition. QuickRx Specialty Pharmacy is an independent pharmacy and is not affiliated with Novartis, Apotex, Cipla, or any pharmaceutical manufacturer.

Last reviewed: December 2025

Reviewed by Julia Kravtsova, PharmD
Head Patient Navigator, QuickRx Specialty Pharmacy

Julia Kravtsova, PharmD, is the Head Patient Navigator at QuickRx Specialty Pharmacy, where she oversees patient care coordination for complex specialty medications including oncology treatments. With extensive experience in specialty pharmacy services, Dr. Kravtsova ensures patients receive comprehensive support from copay assistance enrollment to clinical counseling.

Last Updated: December 2025